Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.

Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Related Content
EBC-129 was well tolerated, with a safety profile consistent with other MMAE-based ADCs in patients with PDAC and other solid tumors.

EBC-129 Shows Early Activity in Advanced Pancreatic Ductal Adenocarcinoma

Jordyn Sava
June 2nd 2025
Article

EBC-129 was well tolerated, with a safety profile consistent with other MMAE-based ADCs in patients with PDAC and other solid tumors.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC

Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC

Jordyn Sava
June 1st 2025
Article

Cisplatin, nab-paclitaxel, gemcitabine, and capecitabine significantly improved EFS vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

EBC-129 Receives FDA Fast-Track Designation for PDAC

Roman Fabbricatore
May 28th 2025
Article

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.

Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen responded.

Avutometinib/Defactinib Combo May Elicit Efficacy in Metastatic PDAC

Roman Fabbricatore
May 27th 2025
Article

Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.